
It's no longer about whether to address metabolic disease like obesity and type 2 diabetes - it’s whether you’ve evaluated every option as you're finalizing your strategy.
Everything you need as you finalize your 2027 plan
Webinar Replay
1 hr
Expert Perspectives
Short clips on the questions that come up most in final stage evaluations.
00:39
Frank Dumont
Virta Executive Medical Director
00:47
01:55
Frank Dumont
Virta Executive Medical Director
Virta's perspective on what benefit leaders need to know.
Coverage is not the same as a strategy. Without a plan for what happens after the prescription, spend compounds year over year with no defined endpoint. Virta pairs personalized nutrition with responsible prescribing so medication becomes a tool rather than a permanent line item. Members achieve weight loss on par with clinical drug trials, with or without a GLP-1.
Proof point: 13% average weight loss without Rx at one year1, against a 4.7% benchmark.
This is the question most strategies do not answer. Weight regain after discontinuation is well documented in the drug trial literature. Virta has published peer-reviewed outcomes on sustained weight loss after GLP-1 deprescription.
Proof point: 85% of weight loss sustained one year after stopping a GLP-12, against a 28% benchmark.
Savings come from medication reduction, fewer complications, and lower utilization as health improves, and they are modeled with third-party validated methodology. Virta puts 100% of fees at risk in the first year for employer partners, so the financial case does not rest on projections alone.
Proof point: $301 to $6603 gross savings per participant per month depending on clinical complexity. Two-year ROI of 1.7:1 to 3.3:1 by program.
Engagement is where most point solutions quietly fail. Virta's enrollment and retention numbers are driven by a dedicated provider and coach model plus a communications program run by Virta.
Proof point: 30% enrollment and 83% retention at one year.4 5 to 10x increase in engagement among employers using Virta-led communications.5
85%
of weight loss sustained one year after GLP-1 deprescription
vs. 28% benchmark
$301-$660
gross savings per participant per month depending on clinical complexity
100%
fees at risk in the first year for employer partners
30%
average enrollment
5-10x increase in engagement with Virta-led communications
Talk with a Virta advisor about how metabolic health fits into your 2027 strategy.